This is a story about a fungus—the cause of some serious infections in hospitalized patients—and a group of microbiologists with McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) who want to develop a new antifungal drug.
Two of the most problematic causes of infections are Enterococcus faecalis, a bacterium, and Candida albicans, a fungus, often found together in the gastrointestinal region. These microbes can also co-habitate in the mouth; some studies have found evidence of both in materials extracted from infected root canals.
The presence of these two microbes in the same parts of the body led Michael Lorenz, Ph.D., a professor of microbiology and molecular genetics at UTHealth, and his colleague, Danielle Garsin, Ph.D., associate professor of microbiology and molecular genetics, to wonder how the organisms might affect one another.
When the researchers put the two organisms together, they noticed something interesting.
“We thought the two together would make infections worse,” Lorenz said. “What ended up happening was unexpected and fascinating: Enterococcus was actually returning Candida to a benign state.”
Doctoral student Carrie Graham deduced that a protein made by the bacterium, EntV, was blocking the fungus’ biofilm development. The interaction was inhibiting the Candida’s virulence, but not harming it. In fact, it was a completely new type of activity for this protein.
Using this newfound knowledge, the researchers wondered if this EntV protein would be effective against a Candida infection, in this case oral thrush—a yeast infection of the mouth and throat that affects millions, particularly babies, seniors and people with weakened immune systems.
In a mouse model, the researchers found that the animals treated with the antimicrobial protein had fewer symptoms—including a reduction in the creamy, white lesions associated with oral thrush—than those who were not treated with the antimicrobial protein. Their results were reported in the April issue of Proceedings of the National Academy of Sciences of the United States of America.
“These findings demonstrate that EntV has potential as an antifungal agent that targets virulence rather than viability,” the researchers wrote in their study.
The next steps are for Garsin’s lab to determine how EntV is produced in Enterococcus, and Lorenz’s lab to determine how EntV makes Candida less infectious. The researchers are also trying to determine how the protein could be used in a clinical setting.
“It’s probably many years away,” Lorenz said, “in part because the protein needs to be modified to make it a suitable therapeutic.”
More testing will determine whether EntV is effective against strains of Candida resistant to traditional antifungals and whether it can be used with them to improve outcomes.
“The long-term goal is to develop a new antifungal drug that takes a different approach to treating oral thrush,” Garsin said.
MD Anderson Cancer CenterMDAnderson
Struggling to find time to care for yourself during your loved one's cancer treatment? Here's how to look after your own health while you're at MD Anderson. #...
MD Anderson Cancer Center@MDAndersonNews
What patient Stacey Fields learned from her first #mammogram: https://t.co/zcRQC4zaKh #womenshealth #endcancer https://t.co/kpwOLdmzcc
Join the Cardiothoracic section of @BCM_Surgery at the third annual Walk for Victory for the Marfan Foundation. Jo… https://t.co/85ir9Iqgv5
If a #Veteran you know is in crisis, #BeThere and contact the Veterans Crisis Line. Learn more:… https://t.co/uSv2kdzEQf
Baylor College of MedicineBaylorCollegeOfMedicine
From the Labs talks with Dr. Chonghui Cheng and learns more about her lab's quest to find how a G-quadruplex helps breast cancer survive.
@DockLineMagInc We appreciate the RT ^SF
@Goble_Warming_ Thanks for sharing ^SF
@bornidentityP Thanks for the shout-out ^SF
This Wednesday, join the Hanszen College Fellows for a lecture with @jameshamblin, senior editor of the… https://t.co/v8Tvx5hKeO
Study to focus on women with limb loss https://t.co/OOyAIaPEXL via @VAResearch
Today’s #VeteranOfTheDay is @USArmy Veteran Chuck Choney https://t.co/HjYS0ddPlv #ArmyVet
U.S. Department of Veterans AffairsVeteransAffairs
Today’s #VeteranOfTheDay is Army Veteran Chuck Choney. Chuck served during the Vietnam War. Chuck was commissioned as a Second Lieutenant through the ROTC prog...
CHI St Luke's Health@CHI_StLukes
RT @GloorLoor: @LungTXfndtn @LungAssociation great time as guest speaker in AZ adv lung tx Symposium @TransplantJrnl @Transmedics @CHI_StLu…
University of Houston@UHouston
RT @uhrecreation: We will be closing at 6PM TONIGHT due to the city of Houston repairing a water leak on spur 5 until midnight. The city wi…
"We do see a moderate reduction in symptoms for those who have been vaccinated but still end up developing fever an… https://t.co/nh9t0H7sUV